Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) of a class action securities lawsuit.
CLASS DEFINITION:
The Fixx lawsuit seeks to recover losses on behalf of Homology investors who were adversely affected by alleged securities fraud between June 10, 2019 and February 18, 2022. Follow the link below to get more information and be contacted by a member of our team:
CASE DETAILS:
The Fixx filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT’S NEXT?
If you suffered a loss in Homology during the relevant time frame, you have until May 24, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU:
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: